BERKELEY, Calif., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Gregory W. Schafer,
chief operating officer of Aduro, will present at the 37th Annual Canaccord Genuity Growth Conference in Boston, MA on
Thursday, August 10, 2017, at 12:00 pm Eastern Time.
To access the live webcasts and subsequent archived recordings of this and other company presentations, please
visit Aduro's website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that
transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural
immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious
diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to
express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed as a treatment
for multiple indications, including mesothelioma, gastric, ovarian, lung and prostate cancers. Additionally, a personalized form of
LADD, or pLADD, is being developed utilizing tumor neoantigens that are specific to an individual patient’s tumor. Aduro's STING
Pathway Activator platform is designed to activate the STING receptor in immune cells, resulting in a potent tumor-specific immune
response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is currently being evaluated in a Phase 1
study in patients with cutaneously accessible metastatic solid tumors or lymphomas. Aduro’s B-select monoclonal antibody platform
is comprised of a number of immune modulating assets in research and preclinical development, including BION-1301, an anti-APRIL
antibody. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For
more information, please visit www.aduro.com.
Contact: Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Susan Lehner 510 809 2137 press@aduro.com
